# A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07321574/  
OnCo record `nct07321574` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ABP1011T in small-cell lung cancer, run by Shanghai AB PharmaTech Ltd., now recruiting.

## Summary

A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT07321574 by Shanghai AB PharmaTech Ltd., with 110 participants planned, started 2025-12-30 and due to reach its primary completion in 2028-11-28. Interventions recorded: ABP1011T.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07321574
- Phase: 2
- Setting: An Open-Label, Multi-Cohort Phase IIb Clinical Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
- Sponsor: Shanghai AB PharmaTech Ltd.
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT07321574: https://clinicaltrials.gov/study/NCT07321574

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)

---
JSON: https://onco.cc/api/v1/entities/nct07321574.json